PMS2 and uterine corpus sarcoma: Genomic alterations classified as oncogenic/likely oncogenic in MLH1, MSH2, MSH6, and PMS2 were present in 89 patients overall (1.3%), including 60 in the STS cohort (1.5%), 11 in the uterine sarcoma cohort (1.8%), nine in the bone sarcoma cohort (0.9%), and nine in the GIST cohort (0.7%).